• FDA cleared a rituximab biosimilar for the US market, strengthening Fresenius Kabi’s oncology and immunology biosimilars portfolio.
• Dr. Reddy’s Laboratories developed, manufactured, and filed the product; Fresenius Kabi holds exclusive US marketing rights under a deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.